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Abstract 
Background: Accurate information about the prevalence of Chlamydia trachomatis is needed to assess 
national prevention and control measures.  
Methods: We systematically reviewed population-based cross-sectional studies that estimated 
chlamydia prevalence in European Union/European Economic Area (EU/EEA) Member States and 
non-European high income countries from January 1990 to August 2012. We examined results in 
forest plots, explored heterogeneity using the I
2
 statistic, and conducted random effects meta-analysis 
if appropriate. Meta-regression was used to examine the relationship between study characteristics and 
chlamydia prevalence estimates.  
Results: We included 25 population-based studies from 11 EU/EEA countries and 14 studies from five 
other high income countries. Four EU/EEA Member States reported on nationally representative 
surveys of sexually experienced adults aged 18-26 years (response rates 52-71%). In women, 
chlamydia point prevalence estimates ranged from 3.0-5.3%; the pooled average of these estimates 
was 3.6% (95% CI 2.4, 4.8, I
2 
0%). In men, estimates ranged from 2.4-7.3% (pooled average 3.5%; 
95% CI 1.9, 5.2, I
2
 27%). Estimates in EU/EEA Member States were statistically consistent with those 
in other high income countries (I
2
 0% for women, 6% for men). There was statistical evidence of an 
association between survey response rate and estimated chlamydia prevalence; estimates were higher 
in surveys with lower response rates, (p=0.003 in women, 0.018 in men).  
Conclusions: Population-based surveys that estimate chlamydia prevalence are at risk of participation 
bias owing to low response rates. Estimates obtained in nationally representative samples of the 
general population of EU/EEA Member States are similar to estimates from other high income 
countries. 
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Introduction  
Surveys of the population prevalence of Chlamydia trachomatis infections (commonly known as 
chlamydia) can provide information about the need for measures to prevent and control infection. C. 
trachomatis is the most commonly reported sexually transmitted infection (STI) and the most 
commonly reported of all notifiable infections in Europe and the USA [1,2]. C. trachomatis causes 
infection in the lower genital tract in women and men, which can result in upper genital tract 
complications and transmission of infection during pregnancy and labour [3,4]. C. trachomatis also 
increases susceptibility to, and infectiousness of, HIV infection [5]. Chlamydia prevalence data for 
adults aged around 25 years and younger are particularly useful for planning control measures because 
young adults are affected most [3]. Health authorities in some European and other high income 
countries recommend screening in this age group to allow both early treatment of asymptomatic 
infection and the prevention of long term complications [6-9].  
National surveillance data report on diagnosed cases of chlamydia infection and reported rates vary 
widely; from two to 600 per 100,000 population in Europe [1]. These figures cannot be used as 
estimates of population prevalence, however. Chlamydia infections are mostly asymptomatic and rates 
of reported infection largely differences in levels of chlamydia testing between countries. Cross-
sectional surveys of a representative sample of the general population (population-based surveys) [10] 
provide less biased estimates of the prevalence of a condition at a particular time than surveys of 
attenders at health care settings. Participation bias can, however, distort estimates of prevalence in any 
survey whenever there is incomplete participation [11]. Participation bias is more severe when the 
prevalence of the condition is low [12] and when participation rates are low, which is likely in surveys 
of sensitive subjects such as sexual behaviour and STI [12]. In several studies of chlamydia infection 
participants had higher levels of demographic characteristics or behaviours associated with chlamydia 
than non-participants [13-15], which would over-estimate prevalence.   
National estimates of chlamydia prevalence in cross-sectional population-based surveys vary 
considerably, even between countries with similar levels of social and economic development [14,16-
19]. Differences in chlamydia prevalence between countries could represent real differences in sexual 
behaviour patterns and chlamydia control efforts, but might also result from variations in study design 
and participation rates. The primary objective of this study was to systematically review studies 
reporting chlamydia prevalence in adult women and men in the general population of the European 
Union and European Economic Area (EU/EEA). A secondary objective was to investigate the 
association between survey response rate and estimated chlamydia prevalence in both EU/EEA and 
other high income countries [20]. 
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Methods 
We conducted a systematic review using a predefined protocol (Supporting information Text S1) and 
reported it in accordance with the guidelines on Preferred Items for the Reporting of Systematic 
Reviews and Meta-Analyses (PRISMA) [21]. The study is part of a project funded by the European 
Centre for Disease Control and Prevention, for which a technical report describes the results of a 
group of literature reviews about chlamydia epidemiology and control [22]. 
Inclusion and exclusion criteria  
Eligible studies designs were: cross-sectional surveys that used population-based sampling methods 
and tested genital specimens from adult women and men for C. trachomatis. Studies with the 
following characteristics were excluded: serological studies and studies sampling only from extra-
genital sites; participant age below 13 years; data published in letters, commentaries and editorials. We 
considered the following specific groups as part of the general population: school students if the 
sampling frame included all schools in the country or in a sub-national geographic region of a country; 
and military recruits in countries with compulsory military conscription. 
The review focussed on adults in EU/EEA Member States at the time of the first database search. We 
included the following countries to improve the generalisability of our findings and statistical power of 
our analyses: non-EU/EEA countries in Europe; high income countries, as defined by the Organisation 
for Economic Cooperation and Development (OECD) [20]. 
Data sources and searches 
We searched Ovid Medline, Embase, Popline and The Cochrane Library from January 1990 to 17
th
 
October 2011 without language restrictions and updated the search on 17
th
 August 2012. Search 
strategies, adapted for each search engine, included terms for “chlamydia infection” and “prevalence” 
and individual names of EU/EEA Member States, or “Europe”, or the non-European high income 
countries Australia, Canada, Israel, Japan, Korea, New Zealand and USA [20]. In addition we 
searched reference lists of potentially eligible studies and asked experts if they were aware of other 
studies. For countries with no publications identified in the first search we then used only the country 
name and the free text term “chlamydia” to find further publications. We included additional data from 
primary studies included in the review even if the additional publications  were published after the 
search deadline. Supporting information Text S1 includes the full search strategy. 
Study selection 
Two suitably qualified reviewers (SR, KA-K) screened the titles and abstracts of all identified articles 
independently. The full text of potentially eligible studies was retrieved and two reviewers (SR, KA-
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K) independently assessed each against predefined inclusion criteria. Studies were translated where 
necessary. A third reviewer (NL) resolved differences between reviewers if necessary. 
Data extraction and quality assessment 
Two reviewers (SR, KA-K, or SW) extracted data independently in duplicate onto standardised piloted 
forms in EpiData (EpiData Association, Odense, Denmark). If multiple publications were associated 
with a study, we extracted data from the primary publication first (assigned as the publication with the 
most detailed description of the survey methods). Data reported in the primary publication were used 
in the case of inconsistencies. The two reviewers compared the extracted data and resolved differences 
by discussion. If there was still a discrepancy, a third reviewer (NL) adjudicated. We did not contact 
authors for additional information. 
The following information was extracted: study design; country; study population (sexually 
experienced only or all participants) and setting (national or sub-national); demographic 
characteristics; numbers eligible, invited and participating; numbers excluded with reasons; number 
with C. trachomatis detected; diagnostic test method; estimated prevalence and 95% confidence 
intervals (CI) reported in the study. 
We used published guidelines for cross-sectional prevalence surveys to assess the risk of bias related 
to methodological aspects of included studies [11]. Two reviewers (SR, KA-K, or SW) assessed each 
study independently. Discrepancies were resolved by discussion or adjudication (NL). The items 
assessed included: representativeness of the target and source populations; similarity of responders and 
non-responders; achievement of planned sample size; use of standardised data collection methods; 
appropriateness of statistical methods; and response rate [11]. We pre-specified criteria to determine 
whether each feature had been adequately addressed, not adequately addressed, or if there was 
insufficient information to decide. The guideline defined an adequate response rate as >80% [11]. Few 
studies attained this level so we also recorded those with response rates of >60% and >70%.  
Data synthesis and analysis 
We analysed data for women and men separately. First, we estimated chlamydia prevalence using the 
number of positive chlamydia tests and the number of people tested. Where authors of included studies 
reported stratified sampling methods we used the published point estimate and 95% CI. Where simple 
random sampling was done and data were available, we calculated chlamydia prevalence (with 
binomial 95% CI).  
We used forest plots to examine estimates of chlamydia prevalence. The I
2
 statistic expressed the 
percentage of variation between estimates in different studies resulting from factors other than random 
variation [23].  As a guide, I
2
 values above 25%, 50% and 75% are suggested as evidence of mild, 
moderate and severe between study heterogeneity. Low values of the I
2
 statistic suggest that variability 
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between estimates is compatible with random variation [23]. Where there was evidence of moderate or 
severe heterogeneity, we explored reasons for this by stratifying studies in pre-defined groups: age ≤25 
years; geographic coverage (national or sub-national); and study population analysed (all adults or 
sexually experienced adults only). Where appropriate, we pooled estimates using random effects meta-
analysis to estimate the average of the study estimates and their 95% CI. 
We calculated a response rate for each study, using an algorithm to define numerators and 
denominators consistent with recommendations of the Council of American Survey Research 
Organisations (CASRO) [24,25]. Where available, the numerator was the number of people providing 
a sample for chlamydia testing and the denominator was the number of eligible subjects asked to 
participate, provide a sample, or sent an invitation for testing.  If the study report did not include these 
numbers we used the number of samples tested, followed by the number of test results used in the 
analysis as the numerator and the number of eligible people as the denominator. We used the 
published response rate in studies that used complex sampling methods and post-stratification 
weighting. It was not possible to calculate a response rate in studies in which the group asked to 
participate is then asked if they have ever had sexual intercourse and chlamydia testing is restricted to 
those who are sexually experienced. In such studies, the calculated response rate is underestimated. 
We used meta-regression to examine the linear association between estimated chlamydia prevalence in 
≤25 year old women and men and the calculated response rate. We applied the sex-specific response 
rate for the whole study to this age group because most study reports did not report age-specific 
response rates. In these analyses, the I
2
 statistic represents the percentage of heterogeneity due to 
factors other than sampling error after taking into account the association between prevalence and 
response rate. We also used meta-regression to analyse the association between estimated chlamydia 
prevalence and the following binary variables: sex (women versus men), age (≤25 years versus >25 
years), geographical setting (national versus sub-national) and response rate as reported in the included 
studies (<60% versus ≥60%).  We included a term for the individual study in the model when 
observations from the same study were not independent. All analyses were done using Stata statistical 
software (Stata 11, StataCorp, Austin, Texas, USA). 
Results  
The search strategy gave a total of 1003 hits after de-duplication (Figure 1). We included 25 primary 
studies (59 publications) in the populations of 11 EU/EEA countries [14,16,17,19,26-46] including 
Croatia, which became a Member State in July 2013 (Figure 1) and 14 studies (32 publications) in five 
non-EU/EEA countries: Switzerland [47], Australia [48-51], Canada [52,53], New Zealand [54] and 
the United States [18,55-59]. We did not find any eligible studies from Israel, Japan or Korea. In the 
included studies, 121,915 (median 953, interquartile range 471 to 2,350) people in total were tested for 
chlamydia. Table 1 summarises the characteristics of each study.  
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Twenty seven studies included women and men [14,16-19,26,29-36,41,43,45,46,48,49,51-54,57-59], 
six included only women [27,37-39,50,55] and six included only men [28,40,42,44,47,56]. The age 
group ranged from 15 to 17 years in a nationally representative survey in Germany [31]  to 15 to 65 
year olds in a single Arctic community in Canada [53]. Included studies ranged from nationally 
representative general health [18] or sexual lifestyle [14,16,17,58] surveys to studies in localised 
populations, designed to test the feasibility of chlamydia screening interventions [43,52,54] or to get 
people tested and treated for chlamydia [42]. All but two studies [38,39] used nucleic acid 
amplification tests (NAAT) for chlamydia diagnosis (Table 1). Supporting information Table S1 lists 
the primary publication for each study and its associated publications. 
Risk of bias assessment  
All included studies were at risk of biases that could affect the estimated chlamydia prevalence 
(Supporting information Table S2). The target population was assessed as being likely to be 
representative of the general population in only 8/39 studies; six studies in EU/EEA Member States 
Croatia [19], France [16], Germany [31], the Netherlands [33], Slovenia [17] and the UK [14] and two 
studies in the USA [18,58]. Seventeen studies described a comparison between participants and non-
participants. More than half of studies (23/39) did not give enough information about the source 
population to determine whether this was representative of the target population.  
Authors of included studies used different denominators and numerators in their reported response 
rates. We calculated a response rate according to our algorithm for all but 4/39 studies [31,41,47,51]. 
Amongst studies in EU/EEA countries, no study had a calculated response rate above 80%. The 
highest response rate (71%) was achieved as part of a national sexual behaviour survey in the UK [14]. 
Four studies had a response rate between 61% and 70% [27,37-39]. The lowest response rates were in 
studies where entire populations in large geographic areas were invited by post; 13% in East Anglia, 
UK [46] and 16% in three regions in the Netherlands [34].  In non-EU countries, the calculated 
response rate was above 80% in two studies [53,58], between 71% and 80% in two studies [18,57] and  
between 61% and 70% in one study [55]. As with EU/EEA Member States, the highest response rates 
were obtained in studies of people who were already taking part in another study [18,53,57,58]. 
Figure 2 shows the number of people included in the analysis and overall estimate of chlamydia 
prevalence for each included study. In EU/EEA countries, estimated prevalence in women ranged 
from 0.2% in sexually experienced 15 to 44 year olds in Barcelona, Spain in a study of human 
papillomavirus infection [37] to 8.0% in sexually experienced 21 to 23 year olds in Aarhus County, 
Denmark [29] and 18 to 25 year olds in London and Avon, UK [43], who were invited to take 
specimens at home in studies examining methods for chlamydia screening (Figure 2). For men point 
prevalence estimates ranged from 0.4% amongst 16 to 17 year olds taking part in a general health 
survey in Germany [31] to 6.9% in sexually experienced male military recruits aged 17 to 32 years in 
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three counties in Denmark [28] (Figure 2). In the two studies that included only teenagers [26,31], 
estimates were lower in men than in women (2.6% vs. 5.0% in Denmark, 0.4% vs. 2.1% in Germany). 
In non-EU/EEA countries, estimated prevalence in women ranged from 0.9% in 18 to 35 year olds in 
Melbourne, Australia [50] to 13.8% in a Canadian Arctic community aged 18 to 65 years [32] (Figure 
2). In men, the lowest estimated prevalences were in 14 to 39 year olds in a general health survey in 
the USA (1.1% [18]) and military recruits aged 18 to 26 years in the French-speaking region of 
Switzerland (1.2% [47]). The highest estimate was from 15 to 39 year olds in a remote community in 
Queensland, Australia (10.6% [48]).  
Figure 3 and Figure 4 show chlamydia prevalence estimates from studies conducted in EU/EEA and 
other high income OECD countries among women and men aged ≤26 years. In nationally 
representative samples of sexually experienced people in five countries, there was no or only mild 
heterogeneity. In women, estimates ranged from 3.0% (95% CI 1.7-5.0%) in the UK [14] to 5.3% 
(95% CI 2.3, 10.2%) in Croatia [19]. The pooled average estimate in all five countries was 4.3% (95% 
CI 3.6, 5.0%, I
2 
0%) (Figure 3) and in the four EU/EEA Member States 3.6% (95% CI 2.4, 4.8%, I
2
 
0%, not shown in the figure).
 
In men, estimates ranged from 2.4% (95% CI 1.0, 5.7%) in France [16] 
to 7.3% (95% CI 3.4, 13.4%) in Croatia [19].  The pooled average estimate in all five countries was 
3.6% (95% CI 2.8, 4.4%, I
2
 6%) (Figure 4) and in the four EU/EEA Member States 3.5% (95% CI 1.9, 
5.2%, I
2
 27%, not shown in the figure). Heterogeneity was severe (I
2
 >75%) in sub-national studies 
and in nationally representative studies with chlamydia prevalence estimates for the whole study 
population in both women and men; we did not estimate pooled averages for these groups of studies 
(Figure 3 and Figure 4). 
There was statistical evidence of an association between overall sex-specific survey response rate and 
estimated chlamydia prevalence in both women and men; estimated chlamydia prevalence was higher 
in surveys with lower response rates (Figure 5, women, P=0.003; men, P=0.018 from meta-
regression). Results were similar if the analysis was restricted to studies that reported age-specific 
response rates for women and men aged ≤25 years (women, 15 studies, I2 80.6%, P=0.004; men, 13 
studies, I
2
 88.6%, P=0.04). When the variable response rate was dichotomised (<60% and ≥60%), the 
ratio of odds for chlamydia infection was 1.9 times higher in studies with response rates <60% than in 
studies with response rates ≥60%. After controlling for national or sub-national study coverage, the 
ratio of odds was 1.7 (95% CI 0.9-3.2, P=0.081). There was no strong evidence of an association 
between estimated chlamydia prevalence and response rate in surveys of nationally representative 
population samples in women (P=0.644, Figure 6A) or men (P=0.729, Figure 6B). In sub-national 
surveys, the meta-regression plot suggests an association between estimated chlamydia prevalence and 
with response rate (Figure 6A and Figure 6B). There was statistical evidence of this association in 
women (P=0.063) but not men (P=0.267) and there was substantial residual heterogeneity between 
prevalence estimates (I
2
 91% women, 81% men). The regression lines for subnational and national 
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surveys approached each other at higher levels of response rates. This suggests that at very high 
response rates, estimated prevalence would be similar in both survey types. 
Discussion 
Main findings 
In this systematic review we found population-based surveys estimating chlamydia prevalence from 
11 EU/EEA Member States, one non-EU/EEA European countries and four other high income 
countries. In nationally representative samples of sexually experienced ≤26 year olds, between study 
heterogeneity was low in women (five studies, range 3.0%, 95% CI 1.7, 5.0% in UK to 5.3%, 95% CI 
2.3, 10.2% in Croatia, pooled estimate 4.3% , 95% CI 3.6, 5.0%, I
2
 0%) and men (five studies, range 
2.4%, 95% CI 1.0, 5.7% in France to 7.3%, 95% CI 3.4, 13.4% in Croatia, pooled estimate 3.6% ,95% 
CI 2.8, 4.4%, I
2
 6.2%). Chlamydia prevalence estimates from population-based surveys conducted in 
sub-national population samples were very heterogeneous, ranging from 0.6% to 10.7% in women and 
1.1% to 5.9% in men aged ≤25 years. Response rates in most included studies were <60%. There was 
statistical evidence of an inverse association between survey response rate and chlamydia prevalence 
estimates in both women (P=0.003) and men (P=0.018). 
Strengths and weaknesses of the review  
Strengths of this review are the broad and inclusive search strategy and the detailed assessment of 
study methodology. We think that we are unlikely to have missed any large published articles, but 
might not have found all unpublished data. Our systematic searches covered studies published until 
August 2012. Since then, we identified one additional large survey of the UK population in 2010 to 
2011 [60], which used methods similar to those of a survey from 1999 to 2000 [14]. Overall response 
rates and estimates of chlamydia prevalence were similar in both surveys. Another strength is that we 
only included studies that used population-based sampling methods to obtain estimates of chlamydia 
prevalence in the general population. Previous systematic reviews have included studies done in health 
care settings [1,61,62], the results of which cannot be easily extrapolated to the general population 
because they include people with symptoms and exposures that put them at higher than average risk of 
chlamydia infection. The inclusion of data from countries outside Europe increased statistical power to 
examine heterogeneity and allowed us to examine the generalisability of our findings to countries with 
similar levels of social and economic development. There was some inconsistency in the countries 
included in the review, however. Bulgaria, Hungary, Romania are EU Member States but not high-
income economies; other high-income EU/EEA economies are not OECD members (Cyprus, Latvia, 
Liechtenstein, Lithuania, Malta). We did not find population-based studies in any of these countries. 
Two main limitations of the review relate to the small number of studies with comparable data and the 
completeness of the data reported. First, we could not calculate a consistent response rate for all 
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studies because of differences between studies in the data reported and differences in study design. We 
overcame this limitation in part by applying an algorithm to select the numerator and denominator that 
were closest to the recommended definition [24]. The recommended numerator and denominator 
cannot be applied, however, in study designs that enrol participants and then restrict chlamydia testing 
to responders reporting sexual experience. In this case, the calculated response rate underestimates the 
true response rate and cannot be corrected unless the percentages excluded because they have not had 
sexual experience are recorded. Second, four countries (Denmark, Netherlands, Sweden, UK) 
accounted 17/25 included studies from EU/EEA countries. The small number of countries contributing 
to the review needs to be considered when interpreting the findings.   
Interpretation 
Estimates of chlamydia prevalence in women and men aged ≤26 years in surveys of nationally 
representative samples of populations in EU/EEA and other high income countries were statistically 
consistent and between study variability was compatible with random variation [23]. The pooled 
estimates for EU/EEA Member States are the average of estimates of chlamydia prevalence from four 
studies and do not mean that this is the chlamydia prevalence across Europe. The chlamydia 
prevalence estimates and their precision need to be interpreted in the context of national differences in 
culture, sexual behaviours and attitudes, health systems and intensity and duration of chlamydia 
control activities [63,64]. Most of the point estimates of chlamydia prevalence were <5% in both 
women and men. Participation bias might still affect these estimates because of low response rates and 
the low estimated prevalence of chlamydia [12]. Over-estimation is more likely than under-estimation 
because responders have higher levels of factors associated with STI than non-responders [14].  
In cross-sectional surveys of chlamydia prevalence, the lower the calculated response rate the higher 
was the estimated prevalence. The association appeared to be more marked in studies conducted in 
sub-national regions of a country than in nationally representative population surveys (Figure 6). 
Differences in the objectives of studies in these groups could help explain this finding. The objectives 
of sub-national studies were diverse. Studies that assessed the feasibility of chlamydia screening 
approaches might have specifically encouraged chlamydia testing by people at high risk of infection 
but have low overall response rates [29,34,45]. Studies designed to measure chlamydia prevalence as a 
main [50] or subsidiary objective [37] might have enrolled a more representative sample of the target 
population. In nationally representative surveys, chlamydia testing was done as a small part of studies 
that were designed to measure a wide range of health-related [58] or sexual health-related behaviours 
[14,16,17]. These studies tended to have higher overall response rates than sub-national studies. Of 
note, the national survey with the highest estimate of chlamydia prevalence, in Croatia, also had the 
lowest response rate [19]. 
Implications for practice, policy and research 
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This review highlights several challenges to determining accurate and comparable estimates of 
chlamydia prevalence between countries. Standard definitions used by survey and market research 
organisations to define target and study populations and to calculate response rates were rarely 
adhered to. Reporting standards for prevalence surveys in epidemiological research, perhaps as an 
extension to existing Standards for the Reporting of Observational Studies in Epidemiology [65] might 
help to improve consistency in future. The association between estimated chlamydia prevalence and 
survey response rate suggests that estimates from studies with very low response rates should not be 
interpreted as estimates of the population chlamydia prevalence, even when sampling has covered a 
whole defined region of a country. This review does not provide data to specify a threshold response 
rate below which the value estimated is unreliable, however. Our review shows that population-based 
chlamydia prevalence has been estimated in a minority of European and other high income countries. 
Surveys among samples representative of national populations in a wider variety of countries, 
particularly in non-high income EU Member States, and in other low and middle income countries 
would be valuable if they use consistent methods and achieve high response rates. Surveys that 
estimate chlamydia prevalence are at risk of participation bias owing to low response rates; estimates 
obtained in nationally representative samples of the general population of EU/EEA Member States are 
similar to estimates from other high income countries. 
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Figure legends  
Figure 1 Flow diagram of study identification, inclusion and exclusion 
Figure 2 Forest plot, overall estimate of chlamydia prevalence in women and men of all ages in 
EU/EEA and other high-income OECD countries in all included studies. CI, confidence interval. The 
small filled diamond shows the point estimate, the lines either side are the 95% CI. Each row is a 
study or group within a study, with separate estimates from women and men, where available. In 
Denmark 2002, Group 1 received home sampling kits, Group 2 had to request a sampling kit by post. 
In USA 2012, separate estimates are reported for five survey cycles of the National Health and 
Nutrition Surveys. In Netherlands 2010, separate estimates were reported separately for Amsterdam 
and Rotterdam 
Figure 3 Forest plot, estimates of chlamydia prevalence in women ≤ 26 years in EU/EEA and other 
high-income OECD countries. CI, confidence interval. The small filled diamond shows the point 
estimate, the lines either side are the 95% CI. Each row is a study or group within a study. In Denmark 
2002, Group 1 received home sampling kits, Group 2 had to request a sampling kit by post. Estimates 
are shown separately for sexually experienced participants only or for the overall sample, in either 
national or sub-national populations 
Figure 4 Forest plot, estimates of chlamydia prevalence in men ≤ 26 years in EU/EEA and other high-
income OECD countries. CI, confidence interval. The small filled diamond shows the point estimate, 
the lines either side are the 95% CI. Each row is a study or group within a study. In Denmark 2002, 
Group 1 received home sampling kits, Group 2 had to request a sampling kit by post. Estimates are 
shown separately for sexually experienced participants only or for the overall sample, in either 
national or sub-national populations 
Figure 5 Meta-regression analysis of chlamydia prevalence estimates in women and men aged ≤25 
years against calculated sex-specific response rate for all women and men in the study, in EU/EEA 
and other high-income OECD countries. The size of the open circle corresponds to the precision of the 
prevalence estimate. n= number of studies. For women, n=27, P=0.003, I
2 
82.4%; men, n=18, 
P=0.018, I
2 
87.6%. 
Figure 6 Meta-regression analysis of chlamydia prevalence estimates in participants of all ages 
against response rate, by national or sub-national study design. Panel A, women; Panel B, men. The 
size of the open circle corresponds to the precision of the prevalence estimate. n= number of studies. 
For women, national studies, n=10, P=0.644, I
2 
46.8%; sub-national studies, n=18 studies, P=0.063, I
2 
91.23%; for men, national studies, n=10, P=0.729, I
2 
57.56%; sub-national studies, n=15 studies, 
P=0.267, I
2 
81.25%. 
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Table 1 Summary of characteristics of included studies  
Study name [ref.] 
 
 
National or 
sub-national 
study 
Sex,  
age in years 
Whole study 
sample, sexually 
experienced only 
or both 
Sample tested,  
test used 
Number invited for testing 
(response rate overall for women 
and men in %) 
Study name (acronym), if known; purpose of study, setting and 
sampling strategy  
 
EU/EEA countries       
Croatia 2011 [19] National W&M 
18-25 
sexually 
experienced 
only 
urine,  
NAAT 
1005 participants 
861 sexually experienced 
280 provided urine sample 
(37.5% women) 
(27.9% men) 
Cross-sectional survey of sexual behaviour and STI prevalence. 
Nationally representative sample from all 21 counties in Croatia, with 
multi-stage probability sampling. 
Denmark 1998 [26] 
 
Sub-national W&M 
mean  
18.0 women 
18.2 men 
sexually 
experienced only 
men first void urine, 
women urine and vaginal 
flush sample,  
NAAT 
2603 women  
928 eligible 
(33.3% women) 
1733 men  
442 eligible 
(24.8% men) 
RCT of home sampling versus usual care. Random sample (half) of all 
high schools in Aarhus County. All students invited. Eligible if sexually 
experienced. (Only data from home sampling group included). 
Denmark 1999 [27] 
 
Sub-national W 
20-29 
whole study 
sample 
cervical swab, NAAT 16345 eligible  
11088 in cohort 
(67.8% women) 
Cohort study about risk factors for cervical cancer. Random sample of 
women born in Denmark, in catchment area of Righospitalet, 
Copenhagen taking part in a cohort study, who had cervical swab sample 
taken by gynaecologist. 
Denmark 2001 [28] Sub-national M 
17-32 
both urine, 
NAAT 
2500 
(53.8% men) 
Cross-sectional survey to estimate chlamydia prevalence. All men in 
Northern Jutland, Aarhus or Copenhagen counties liable for military 
service and seen by a medical board. 
Denmark 2002 [29] Sub-national W&M 
21-23 
sexually 
experienced only 
men first void urine, 
women vaginal flush 
sample, 
NAAT 
4000 women  
(32.5% women Group 1) 
(26.3% women Group 2) 
5000 men 
(25.9% men Group 1) 
(15.4% men Group 2) 
RCT on effectiveness of outreach screening strategies. Simple random 
sample from all residents of Aarhus County in this age group. Group 1 
received sampling kit, group 2 had to request kit by post.  
Estonia 2008 [30] Sub-national W&M 
18-35 
whole study 
sample 
men urine, women vaginal 
swab, 
NAAT 
1398 reachable 
(48% women) 
(32% men) 
Cross-sectional survey to estimate chlamydia prevalence. Stratified 
random sample of residents of Tartu county.  
France 2010 [16] National W&M 
18-44 
sexually 
experienced only 
men urine, women vaginal 
swab (or urine), 
NAAT 
4957 eligible by age and sexual 
experience 
(54.4% women) 
Sexual behaviour survey (subsample of Contexte de la Sexualité en 
France study, NatChla). Random subsample of sexually experienced 
people from a national population-based survey on sexual behaviour with 
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(49.3% men) two-phase stratified sampling. Urine testing kit only sent to women if no 
swab returned after 1 month. 
Germany 2012[31]  
 
National W&M 
12-17 
 
both urine, 
NAAT 
5755 in this age group 
(response rate 63% for ages 14-17) 
General health survey (Kinder und Jugendgesundheitsstudie, KiGGS). 
Two-stage stratified cluster sampling, nationally representative sample of 
0-17 year olds. Only tested samples from participants in this age group.  
Netherlands 2000 [32] Sub-national W&M 
15-40 
whole study 
sample 
first void urine, 
NAAT 
5714 women 
(50.8% women) 
5791 men 
(33.0% men) 
Cross-sectional survey to estimate chlamydia prevalence and screening 
feasibility. Simple random sample of patients on the lists of 16 general 
practices in Amsterdam. 
Netherlands 2005 [33] National W&M 
15-29 
both urine, 
NAAT 
20791 
(47.0% women) 
(33.0% men) 
Cross-sectional survey to estimate chlamydia prevalence and screening 
feasibility (CT PILOT). Stratified probability sample of randomly 
selected men and women in 4 regions of the Netherlands according to 
population density. Regions not sampled at random.  
Netherlands 2010 [34] Sub-national W&M 
16-29 
sexually 
experienced only 
men urine, 
women vaginal swab or 
urine, 
NAAT 
139919 Amsterdam
 a
 
(22.4% women) 
(10.8% men) 
103335 Rotterdam 
 
(19.6% women) 
(10.5% men) 
Cluster controlled trial of chlamydia screening effectiveness (Chlamydia 
Screening Implementation, CSI). All 16-29 year old residents of 
Amsterdam, Rotterdam, parts of South Limburg. Sexually active people 
invited to request test kit. South Limburg excluded because eligibility 
depended on response to questionnaire assessing risk of chlamydia. 
Norway 2005 [35] Sub-national W&M 
18-29 
whole study 
sample 
urine, 
NAAT 
646 reached  
(43.8% women) 
(25% men) 
Cross-sectional survey to estimate chlamydia prevalence. All patients on 
the list of a group practice in Oslo. 
Norway 2012 [36] Sub-national W&M 
18-25 
sexually 
experienced only 
urine, 
NAAT 
10000 invited,  
1670 returned sample  
(18.9% women) 
(11.9% men) 
Cross-sectional survey to estimate chlamydia prevalence. Simple random 
sample of 10,000 people in this age group living in Rogaland county 
using unique personal identification number. 
Slovenia 2004 [17] National W&M 
18-49 
both first void urine, 
NAAT 
2616 invited 
(60.0% women) 
(50.9% men) 
Sexual behaviour study. Stratified two stage probability sample of the 
general population of Slovenia in this age group. All participants invited 
to provide specimen for chlamydia testing. 
Spain 2007 [37] 
 
Sub-national W 
15-44 
sexually 
experienced only 
cervical swab, 
NAAT 
1821 invited 
916 reached or accepted 
(66.1% women) 
Cross-sectional multinational HPV prevalence survey. Random age 
stratified sample of the adult female general population from census list 
of 4 urban communities in metropolitan Barcelona. 
Sweden 1992 [38] Sub-national W 
15-34 
sexually 
experienced only 
cervical and urethral 
swabs, 
EIA (± direct IF) 
543 reached and were sexually 
experienced 
(68.9% women) 
Cross-sectional survey to estimate chlamydia prevalence. All women in 
this age group in a primary health care area in Nättraby invited, only 
sexually experienced screened. 
Sweden 1995 [39] 
 
Sub-national W 
19,21, 
23,25 
whole study 
sample 
cervical and urethral 
swabs, 
culture 
816 reached 
611 participated 
(68.3% women) 
Cross-sectional survey to estimate chlamydia prevalence. All women of 
this age living in primary health care area of Ålidhem community centre 
in Umeå. 
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Sweden 2003 [40] Sub-national M 
22 
whole study 
sample 
first void urine, 
NAAT 
1074  
(35.6% men) 
Cross-sectional survey to investigate feasibility of chlamydia screening. 
All males of this age living in Umeå. 
Sweden 2004 [41] Sub-national W&M 
20-24 
whole study 
sample 
first void urine, 
NAAT 
200 
(65% women) 
(45% men) 
Cross-sectional survey to estimate chlamydia prevalence and cost-
effectiveness of home sampling. Simple random sample of 100 men and 
100 women in this age group living in Umeå. 
Sweden 2007 [42] 
 
Sub-national M 
19-24 
whole study 
sample 
first void urine, 
NAAT 
1936 reached 
(14.5% men) 
Cross-sectional survey to estimate chlamydia prevalence. Sampling 
method unclear, 1000 men living in Uppsala county (from population 
register), and 1000 Uppsala university students (from student register 
database).  
United Kingdom 2000a 
[44]  
Sub-national M 
18-35 
whole study 
sample 
first pass urine, 
NAAT 
919 invited by post and reachable 
(45.3% men) 
Cross-sectional survey to estimate chlamydia prevalence and screening 
feasibility. Postal recruitment of all men aged 18-24 and a random sample 
of men aged 25-35 in 4 general practices in North West London. 
United Kingdom 2000b 
[43]  
Sub-national W&M 
18-35 
sexually 
experienced only 
men urine, women urine or 
vulval swab, 
NAAT 
166 women reached 
(39% women) 
175 men reached 
(46% men) 
Pilot study of acceptability of home sampling. Simple random sample of 
patients on the lists of 3 general practices in North West London and 
Avon. Urine samples from random 50% of women, vulval swabs from 
other 50%. 
United Kingdom 2001 
[14] 
National W&M 
18-44 
sexually 
experienced only 
urine, 
NAAT 
5026 invited to give urine sample
 
 
(total 11 161 interviewed) 
(71.1% women)
 b
 
(68.7% men) 
Sexual behaviour study (National Survey of Sexual Attitudes and 
Lifestyles, Natsal-2). Random sample of sexually experienced people 
taking part in a stratified probability sample of people aged 16-44 years 
resident in the United Kingdom.  
United Kingdom 2007 
[45] 
 
Sub-national W&M 
16-39 
whole study 
sample 
men first void urine, 
women first void urine and 
vulvo-vaginal swab , 
NAAT 
14382 reached 
(37.6% women) 
(27.9% men) 
Cross-sectional survey to estimate chlamydia prevalence and screening 
feasibility (Chlamydia Screening Studies project, ClaSS). Random 
sample of general population in Birmingham and Bristol areas, selected 
from 27 general practice lists. 
United Kingdom 2012 
[46] 
Sub-national W&M 
18-24 
whole study 
sample 
urine, 
NAAT 
29917 invited 
(13.2% women) 
(9.8% men) 
Cross-sectional survey investigating feasibility of postal screening 
invitations. All people in this age group registered with any GP in North 
East Essex Primary Care Trust. 
Non-EU/EEA countries, Europe      
Switzerland 2008 [47] Sub-national M 
18-26 
both first void urine,  
NAAT 
521 eligible and gave written consent 
(cannot calculate) 
Cross-sectional survey to estimate chlamydia prevalence. All young 
Swiss men attending obligatory medical board before army recruitment 
(French speaking region only). 
Non-EU/EEA countries, high income OECD     
Australia 2003 [48] 
 
Sub-national W&M 
15-40+ 
whole study 
sample 
first catch urine,  
NAAT 
6431 eligible 
2862 participated 
(43.8% for women and men) 
 
General health survey. All people living in 26 rural indigenous Australian 
and Torres Strait Islander communities in northern Queensland taking 
part in Well Person’s Health Check.  
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Australia 2004 [49] Sub-national W&M 
15-35 
whole study 
sample 
men first void urine, 
women vaginal swab, 
NAAT 
2703 eligible listed 
1219 screened 
(50.7% women) 
(39.3% men) 
Cross-sectional survey to estimate chlamydia and gonorrhoea prevalence. 
Indigenous Australian people aged 15-35 living in Alice Springs area 
Australia 2006 [50] Sub-national W 
18-35 
both first void urine,  
NAAT 
1532 eligible households 
979 women interviewed 
657 gave urine sample 
(42.9% women) 
Cross-sectional survey to estimate chlamydia prevalence. Simple random 
sample from Melbourne residential telephone directory. 
Australia 2008 [51] 
 
Sub-national W&M 
14-40 
whole study 
sample 
men first void urine, 
women low vaginal swabs, 
NAAT 
ca. 1300 in 1996 
(cannot calculate) 
Cross-sectional survey in STI control programme screening for 
chlamydia, gonorrhoea and syphilis. All resident indigenous Australians 
living in the Anangu Pitjantjatjara Yankunytjatjara Lands. 
Canada 2002 [52] Sub-national  W&M 
15-39 
whole study 
sample 
first catch urine,  
NAAT 
1075 women 
(29.3% women) 
1130 men 
(16.2% men) 
Chlamydia mass screening study.  All adults from remote Inuit 
communities in Nunavik region. All sexually experienced or in this age 
group especially encouraged to take part. 
Canada 2009 [53] Sub-national W&M 
15-65 
whole study 
sample 
urine, 
NAAT 
224 estimated eligible 
(cannot calculate)181 screened 
(80.8% for women and men) 
Chlamydia and gonorrhoea mass screening study.  All men and women in 
this age group living in a rural Inuit community from Baffin Region, 
Nunavut.  
New Zealand 2002 [54] 
 
Sub-national           W&M 
16+ 
sexually 
experienced only 
urine, 
NAAT 
1582 invited 
1136 consented 
582 sexually active 
(cannot calculate) 
Cross-sectional survey to estimate chlamydia prevalence. Random sample 
of 50% of classes in all private and public high schools, Christchurch. 
Only sexually active had their samples tested.  
USA 2001 [55] Sub-national W 
18-29 
sexually 
experienced 
only 
urine,  
NAAT 
2148 eligible 
1439 enrolled 
1370 tested 
1314 sexually active 
(61.2% women) 
Household survey of risk behaviour and chlamydia prevalence. All 
English- or Spanish-speaking women in this age group in a random 
sample of low income housing blocks from the 1990 census (<10
th
 
percentile) in 3 counties in California. 
USA 2002a [56] National M 
18-19, 
22-26 
whole study 
sample 
urine, 
NAAT 
1995 survey: data from 470 aged 18-
19, and 995 aged 22-26 who were 
aged 15-19 in 1988 survey 
(cannot calculate)  
National Surveys of Adolescent Males (NSAM). Sexual health survey. 
Nationally representative sample of never-married, non-institutionalised 
men aged 15-19 (1995 survey), and aged 22-26 (aged 15-19 in 1988 
survey but re-interviewed in 1995). Oversampling of black and Hispanic 
youths.  
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USA 2002b [57] 
 
Sub-national W&M 
18-35 
whole study 
sample 
urine, 
NAAT 
1224 adults aged 18-45 reached 
728 age-eligible for screening  
(79.5% women and men) 
Cross-sectional survey to estimate chlamydia and gonorrhoea prevalence. 
Stratified probability sampling of households in Baltimore; urine samples 
requested from those in study age group. 
USA 2004 [58] 
 
National W&M 
18-26 
both first void urine,  
NAAT 
Wave I: 18924 
Wave III: 14322 
(84% women and men) 
Cohort study (US National Longitudinal Study of Adolescent Health, 
Add Health). Nationally representative sample of young people in the 
USA.   
USA 2011 [59] 
 
Sub-national W&M 
15-35 
both urine, 
NAAT 
4998 eligible 
(42.7% women and men) 
Cross-sectional survey to estimate STI prevalence (Monitoring STI 
Survey Program). Probability sample of Baltimore residents.  
USA 2012 [18] 
 
National W&M 
14-39 
whole study 
sample 
urine, 
NAAT 
20836 selected 
17190 interviewed 
(women 80.4%, 2007-2008)
 c
 
(men 74.5%, 2007-2008) 
General health survey (US National Health and Nutrition Examination 
Surveys, NHANES). Stratified multistage probability cluster sampling. 
Data from five 2-year survey cycles.  
 
Abbreviations: EIA, enzyme immunoassay test; EU/EEA, European Union or European Economic Area Member States; IF, immunofluorescence test; M, men; 
NAAT, nucleic acid amplification test; OECD, Organization for Economic Cooperation and Development; STI, sexually transmitted infections; W: women.   
a
 numbers from van den Broek et al. 2012, 1
st
 invitation; [66] 
b
 numbers from technical report Erens et al. 2001; [24] 
c 
response rates from online results for 2007-2008 http://www.cdc.gov/nchs/nhanes/response_rates_CPS.ht
All publications identified
N= 1310
MEDLINE n= 622, EMBASE n= 412, 
Popline n= 115, Cochrane n= 12
Additional searches n=81
Reference lists n= 49
Experts n=19 
Title and abstract screening
N= 1003
Excluded:
N= 307 duplicates
Excluded:       
N= 503 publications 
Topic not relevant, n= 39
Country not of interest, n= 7
Narrative Review, n= 35
Specimen not from urogenital-tract, n= 18 
Age < 13 years, n= 1
If AUS/CAN/NZ/USA or non-EU/EFTA-Europe, not 
general population, n= 239 
Other, n= 56
Study type/design not relevant, n = 108
Potentially eligible publications
N= 422
Excluded:
N= 78 publications 
Narrative Review, n=2
If non-EU/EEA 
Not general population, n=15
Other, n=17
Study type/design not relevant, n=3
Laboratory or surveillance data, n=32
Self-reported data, n=9
Included in review
Publications: N=91
EU/EEA n=59 (25 studies, 11 countries)
Non-EU/EEA n=32 (14 studies, 5 countries)
Excluded
N= 331 publications 
Other settings in countries with general 
population study, n = 234 
Not population-based in EU/EEA 
countries with no general population 
study, n=82 
Systematic reviews, references checked 
only, n=15
Full text screening
N= 500
countries 
with no general population study, n=82 
Systematic reviews, references checked 
only, n=15
Figure 1
EU/EEA Member States
Denmark 1998 [26] women
men
Denmark 1999 [27] women
Denmark 2001 [28] men
Denmark 2002   Group 1 women
[29] men
Group 2 women
men
Estonia 2008 [30] women
men
France 2010 [16] women
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Figure 2
NOTE: Weights are from random effects analysis.
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NOTE: Weights are from random effects analysis.
National population, overall
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Slovenia 2004 [17]
USA 2004 [58]
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Subtotal (I-squared = 84.5%, p = 0.000)
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1. Background
Chlamydia trachomatis infection is the most commonly reported sexually transmitted 
infection in Europe [1]. Young adult women and men under the age of 25-30 years are the 
population group most likely to be infected [2]. In women, the bacteria can ascend from the 
endocervix, resulting in upper genital tract infection. This can cause pelvic inflammatory 
disease with potential sequelae of tubal factor infertility, ectopic pregnancy or chronic pelvic 
pain. C. trachomatis has been identified in the placenta of infected pregnant women [3] and 
infection during pregnancy is associated with prematurity [4]. Infection of the neonate during 
labour can lead to severe conjunctivitis and pneumonia [2]. In men, ascending chlamydia 
infection can lead to epididymitis. Additional complications that are more common in men 
than women include reactive arthritis and Reiter’s syndrome. For both sexes, chlamydia 
infection increases susceptibility and transmission of HIV [5]. Complications of genital tract 
infection with C. trachomatis can impair quality of life in women [6] and result in substantial 
costs to the healthcare system [7]. 
Chlamydia infection is preventable and treatable [8].Chlamydia infection can be treated with 
antibiotics. A single dose of azithromycin or a seven day course of doxycycline is efficacious 
for short term microbiological cure of C. trachomatis  in 97-98% of cases [9]. Partner 
notification and management are essential parts of chlamydia case management for 
identifying infected cases and preventing re-infection in the index case [10]. Most chlamydia 
infections are, however, asymptomatic or cause non-specific symptoms, which are often not 
recognised, particularly in women. Screening of people at high risk of infection is 
recommended in several European and other high income countries to identify and treat 
asymptomatic infections and to prevent long term complications [11-14].   
Surveys of the population prevalence of C. trachomatis infections (chlamydia) can provide 
information for health policy decision makers about the need for measures to prevent and 
control infection. The least biased estimates of the prevalence of any condition at a particular 
time come from cross-sectional surveys of a representative sample of the general population 
(population-based surveys) [15]. Several large population-based surveys of chlamydia 
infection have been done in European Union (EU) Member States such as Great Britain [16] 
and the Netherlands [17] and other countries such as the USA [18]. Estimates of chlamydia 
prevalence vary between studies, even across countries with similar levels of social and 
economic development. Differences in estimates between countries could be real 
(representing differences in sexual behaviour patterns and chlamydia control efforts), but 
might also result from variations in study design and participation rates. A systematic review 
of chlamydia prevalence surveys would allow the available data to be collated and 
differences between studies to be investigated.  
This systematic review is part of a project, Chlamydia Control in Europe, initiated, funded and 
conducted under a framework contract by the European Centre for Disease Prevention and 
Control (Framework Contract ECDC/2011/031). The main objective of the project was to 
provide information about Member States of the EU and European Economic Area (EEA). 
For this review, we will cover other countries in Europe and internationally to examine 
consistency and increase the generalisability of our findings.  
2. Objective
To systematically review surveys estimating the prevalence of C. trachomatis infection in the 
general population of EU/EEA Member States and other high income countries. 
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3. Methods
3.1. Review questions 
1. What is the prevalence of C. trachomatis infection in the general population of the
EU/EEA Member States and other high income countries?
2. What is the distribution of chlamydia infection in different age, sex and ethnic groups?
3. What methodological features of cross-sectional studies influence estimates of C.
trachomatis prevalence?
3.2. Inclusion criteria 
Using the PICOS (population, intervention, comparison, outcome, study design) framework 
for defining systematic review questions: 
3.2.a. Population 
 General population of EU (http://europa.eu/about-eu/countries/member-countries/) 
and EEA (http://www.efta.int/eea) Member States, as of October 2011: Austria, 
Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, 
Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, 
Slovenia, Spain, Sweden and United Kingdom;  
 General population of non-EU/EEA European countries, the USA, Canada, Australia, 
and New Zealand. During the course of the review, before statistical analysis, we 
decided to include all high income countries, using the definition of the Organisation 
for Economic Co-operation and Development (OECD, 
http://www.oecd.org/tad/crc.htm); 
 Adults and young people aged 13 years and over; 
 Women and men. 
3.2.b. Intervention 
Not relevant to this review of observational studies 
3.2.c. Comparison group 
Not relevant to this review of observational studies 
3.2.d. Outcome  
C. trachomatis infection, defined as a positive result of diagnostic tests used by the study 
investigators.  
3.2.e. Study design 
Surveys using methods to obtain a representative sample of the general population or a 
whole country or sub-national region of a country in one of the following study designs: 
 Cross-sectional surveys; 
 Baseline survey in randomised controlled trials or cohort studies; 
 Systematic review if original data were reported; 
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 Specimens taken from the urogenital-tract; 
3.3. Exclusion criteria 
 Countries other than those mentioned above; 
 Serological studies and other studies sampling only from extra-genital sites; 
 Narrative reviews about C. trachomatis that do not contain original data; 
 Participant age below 13 years; 
 Letters, commentaries and editorials. 
3.4. Search strategy 
3.4.a. Electronic databases 
The following databases will be searched from January 1990 to October 2011. The search 
will be updated before starting statistical analysis. We will not apply any language 
restrictions: 
 Ovid Medline;
 Embase;
 Popline;
 The Cochrane Library.
3.4.b. Search terms 
We will use Medical Subject Headings (MeSH) and explosion search terms for searching 
Medline and corresponding thesaurus terms for other databases where available, combined 
using Boolean operators:  
 Chlamydia trachomatis OR chlamydia infections (NOT Chlamydophila pneumoniae OR
trachoma) AND 
 Names of any eligible individual countries (including historical names from 1990 because
‘German Federal Republic’, ‘German Democratic Republic’, Czechoslovakia and 
Yugoslavia do not appear in the exploded search term) AND  
 Prevalence
Search strategies for each database are shown in Appendix 1. 
3.4.c. Additional searches 
 Reference lists: if retrieved publications include source references for potential 
studies about the prevalence of C. trachomatis infections we will retrieve the originals; 
 We will contact experts in the field to ask if they know of any additional publications 
not identified by the search strategy. 
3.4.d. De-duplication 
We will use Endnote bibliographic software for reference management. The following rules 
will be used to remove duplicate hits from the database: 
1. Compare the title, or various combinations of author, year, secondary title, volume,
issue and pages through the ‘de-duplication’ function;
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2. Visually compare the full records of suspected duplicates;
3. Save duplicates in a separate database.
3.5. Selection of eligible studies 
Two suitably qualified reviewers will screen titles and abstracts of articles identified by the 
search strategy independently, using a form to document potential eligibility. Any study 
selected as being potentially eligible by either reviewer, will be retained for review of the full 
text. Where no abstract is available electronically, and eligibility cannot be judged from the 
title alone, the full text of the article will be retrieved and screened. The abstracts of articles 
identified through additional searches will be reviewed in the same manner as those 
identified through database searches. 
Data will be entered into Epidata (Epidata version 3.1, EpiData Association, Odense, 
Denmark). The items included in the screening form are listed in Appendix 2. 
3.5.a. Retrieval of full-text articles 
We will obtain the full text of articles or other documents reporting studies identified as being 
potentially eligible for inclusion. We will make every effort to locate documents through 
internet downloads, inter-library loans and contacting authors of reviews citing potentially 
eligible documents. We intend to have articles translated if necessary to confirm or refute 
eligibility. 
3.5.b. Selection of studies for final inclusion 
The two independent reviewers will examine full text articles using a more detailed form and 
compare their lists of studies eligible for inclusion. Studies identified by both reviewers as 
being eligible for inclusion and having adequate data for extraction will be included in the 
review. Where there are discrepancies, the reasons for these will be discussed and a 
decision about inclusion reached by consensus. If there is no agreement, a third independent 
reviewer will adjudicate to make a final decision about eligibility. The selection of studies is 
described in a flow chart, and will be included in the publication of the review results. A 
version of the proposed flowchart is included as Appendix 3. 
3.5.c. Selecting a population for each country 
We aim to identify surveys in each eligible country, carried out in a sample that is 
representative of the general population. We consider the following groups as part of the 
general population: school students if the sampling frame included all schools in the country 
or in a sub-national geographic region of a country; and military recruits in countries with 
compulsory military conscription. 
As part of the overall project, for EU/EEA Member States only, we aim to catalogue surveys 
estimating levels of chlamydia infection in other settings, such as health-care facilities or 
outreach studies. We defined categories, according to setting and population (Appendix 4). 
3.6. Data extraction 
Two appropriately qualified reviewers will extract and enter data independently from each 
included study into Epidata (Appendix 5).  
Articles in languages other than English will be either translated first and then duplicate data 
extraction conducted as above or, if there are two reviewers who understand the language of 
publication, they will extract the data directly.  
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The two files will be compared using the validation function available in Epidata. 
Discrepancies in data extraction or data entry will be resolved by consensus. If there is no 
agreement a third independent reviewer will adjudicate to make a final decision.  
Some studies may be excluded at the data entry stage if it became apparent that inclusion 
criteria are not met or there is not enough information in the documents to extract the 
required data.  
3.6.a. Data extraction forms 
The following outcomes will be extracted using Epidata (detailed list of items in Appendix 2b): 
 Study design; 
 Country; 
 Population setting: general population of whole country or sub-national population of 
area; 
 Study population: sexually experienced only or all participants; 
 Sex, age and ethnic group of participating individuals; 
 Social-demographic characteristics, specified if not concerning the general 
population; 
 Numbers eligible, invited, accepting participation, providing samples, samples tested, 
number of samples included in analysis; 
 Numbers excluded, with reasons; 
 Diagnostic test method; 
 Numbers with positive C. trachomatis test result; 
 Authors’ estimated prevalence and 95% confidence intervals (CI); 
 Comparison of responders vs. non-responders, if reported; 
 Methodological and reporting quality (Adapted from Boyle, Guidelines for evaluation 
of prevalence studies) [15] (Appendix 6). 
3.7. Data analysis 
3.7.a. Descriptive analysis 
Review questions 1 and 2: C. trachomatis prevalence estimates 
We will tabulate estimates of prevalence from each study. Where complex sampling methods 
had been used we will use the 95% CI presented in published papers. Where simple random 
sampling has been done and data are available, we will calculate C. trachomatis prevalence 
(with binomial 95% CI) for the available sex, age and ethnic groups.  
We will display estimates in forest plots to show the point estimate and confidence intervals 
for each study. 
We will calculate response rates to each survey, based on data provided about the eligible 
population. Using algorithms defined by the Council of American Survey Research 
Organizations (CASRO) [19, 20] we will exclude respondents who were ill, away from home 
or unable to speak English, where possible. We will use authors’ reported response rates in 
complex surveys involving post-stratification weighting. 
University of Bern, 28.12.2013 7 
3.7.b. Statistical analysis 
We will use meta-analysis to combine estimates of chlamydia prevalence where appropriate 
and to examine evidence of between study heterogeneity. 
We will use the I2 statistic to describe the percentage of the variability of results between 
studies that is due to factors other than random variation [21]. As a guide, I2 values above 
25%, 50% and 75% are suggested as evidence of mild, moderate and severe between study 
heterogeneity. Where there is evidence of moderate or severe heterogeneity, we will explore 
reasons for this by stratification or, if enough studies are available, by meta-regression.  
Review question 3 
We will examine the influence of setting, response rate, and other study characteristics using 
meta-regression to examine reasons for heterogeneity. We will examine the linear 
association between estimated chlamydia prevalence and the calculated response rate.  
All analyses will be done using Stata statistical software (Stata 11, StataCorp, Austin, Texas, 
USA). 
4. Report writing
Reports will be written following preferred reporting items for reporting of systematic reviews 
and meta-analyses (PRISMA) guidelines [22]. 
5. References
1. European Centre for Disease Prevention and Control. Sexually transmitted infections in
Europe 2011. Stockholm: European Centre for Disease Prevention and Control; 2013. 
2. Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Corey L et al. Sexually
Transmitted Diseases. New York: McGraw-Hill; 2008. 
3. Rours GI, de Krijger RR, Ott A, Willemse HF, de GR, Zimmermann LJ et al. Chlamydia
trachomatis and placental inflammation in early preterm delivery. Eur J Epidemiol. 
2011;26(5):421-8. doi:10.1007/s10654-011-9569-2. 
4. Rours GI, Duijts L, Moll HA, Arends LR, de Groot R, Jaddoe VW et al. Chlamydia
trachomatis infection during pregnancy associated with preterm delivery: a population-
based prospective cohort study. Eur J Epidemiol. 2011;26(6):493-502. 
doi:10.1007/s10654-011-9586-1. 
5. Cohen MS, Hoffman IF, Royce RA, Kazembe P, Dyer JR, Daly CC et al. Reduction of
concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of 
sexual transmission of HIV-1. Lancet. 1997;349(9069):1868-73.  
University of Bern, 28.12.2013 8 
6. Smith KJ, Tsevat J, Ness RB, Wiesenfeld HC, Roberts MS. Quality of life utilities for pelvic
inflammatory disease health states. Sex Transm Dis. 2008;35(3):307-11. 
doi:10.1097/OLQ.0b013e31815b07dd. 
7. Owusu-Edusei K, Jr., Chesson HW, Gift TL, Tao G, Mahajan R, Ocfemia MC et al. The
estimated direct medical cost of selected sexually transmitted infections in the United 
States, 2008. Sex Transm Dis. 2013;40(3):197-201. 
doi:10.1097/OLQ.0b013e318285c6d2. 
8. Ward H, Fredlund H, Gotz H, Goulet V, Robinson A, Uuskula A. ECDC Guidance.
Chlamydia control in Europe, June 2009. Stockholm: European Centre for Disease 
Prevention and Control; 2009. 
9. Lau C-Y, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a
meta-analysis of randomized clinical trials. Sex Transm Dis 2002;29(9):497-502. 
10. Ferreira A, Young T, Mathews C, Zunza M, Low N. Strategies for parttner notification for
sexually transmitted infections, including HIV. Cochrane Database Syst Rev 2013; Issue
10. Art. No.: CD002843. DOI: 10.1002/14651858.CD002843.pub2.
11. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment
Guidelines, 2010. Morbid Mortal Weekly Rep. 2010;59(RR-12):44-5.
12. Royal Australian College of General Practitioners. Guidelines for Preventive Activities in
General Practice. Melbourne: RACGP; 2007.
13. National Chlamydia Screening Programme. National Chlamydia Screening Programme,
England. Core requirements. 5th Edition, update 2 - August 2010. London: Health
Protection Agency; 2010.
14. Meyers DS, Halvorson H, Luckhaupt S, Force USPST. Screening for chlamydial
infection: an evidence update for the U.S. Preventive Services Task Force. Ann Intern
Med. 2007;147(2):135-42.
15. Boyle MH. Guidelines for evaluating prevalence studies. Evidence Based Mental Health.
1998;1(2):37-9.
University of Bern, 28.12.2013 9 
16. Fenton KA, Korovessis C, Johnson AM, McCadden A, McManus S, Wellings K et al.
Sexual behaviour in Britain: reported sexually transmitted infections and prevalent genital
Chlamydia trachomatis infection. Lancet 2001;358(9296):1851-4.
17. van Bergen J, Götz H, Richardus J, Hoebe C, Broer J, Coenen A. Prevalence of
urogenital Chlamydia trachomatis increases significantly with level of urbanisation and
suggests targeted screening approaches: results from the first national population based
study in the Netherlands. Sex Transm Infect. 2005;81(1):17-23.
18. Miller WC, Ford CA, Morris M, Handcock MS, Schmitz JL, Hobbs MM et al. Prevalence of
chlamydial and gonococcal infections among young adults in the United States. JAMA
2004;291(18):2229-36.
19. Erens B, McManus S, Field J, Korovessis C, Johnson AM, Fenton K et al. National
Survey of Sexual Attitudes and Lifestyles II: Technical Report. London: National Centre
for Social Research; 2001.
20. Council of American Survey Research Organizations. On the definition of response rates.
www.casro.org. 1982.
www.casro.org/resource/resmgr/docs/casro_on_definitions_of_resp.pdf.
21. Higgins J, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Stat Med
2002;21(11):1539-58.
22. Moher D, Liberati A, Tetzlaff J, Altman DG, The Prisma Group. Preferred Reporting Items
for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med.
2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097.
University of Bern, 28.12.2013 10 
Appendix 1: Search strategies 
Ovid Medline 
1. ('chlamydia infections' not ('chlamydophila pneumoniae' or trachoma or 
'lymphogranuloma venereum')).mp. 
2. prevalence.mp. 
3. europe/ or exp austria/ or exp belgium/ or europe, eastern/ or exp baltic states/ or exp 
bulgaria/ or exp czech republic/ or exp hungary/ or exp poland/ or exp romania/ or exp 
slovakia/ or exp slovenia/ or exp yugoslavia/ or exp finland/ or exp france/ or exp 
germany/ or exp great britain/ or exp greece/ or exp iceland/ or exp ireland/ or exp italy/ or 
exp liechtenstein/ or exp luxembourg/ or exp mediterranean region/ or exp netherlands/ or 
exp portugal/ or exp scandinavia/ or exp spain/ or exp switzerland/ or czechoslovakia/ or 
european union/ canada/ or united states/ or australia/ or new zealand/ japan/ or korea/ or 
israel/ 
4. prevalence.mp. or mass screening/mt 
5. (austria or belgium or estonia or latvia or lithuania or bulgaria or czech republic or 
hungary or poland or romania or slovakia or slovenia or yugoslavia or finland or france or 
germany or great Britain or greece or iceland or ireland or italy or liechtenstein or 
luxembourg or malta or cyprus or netherlands or portugal or norway or sweden or 
denmark or spain or switzerland or czechoslovakia).mp. 
6. 1 and 2 and 3 
7. 1 and 4 and 5 
8. 6 and 7 
9. Limit 8 to (humans and yr=”1990 –Current”) 
Limits: 1990-current, humans; homepage: http://ovidsp.tx.ovid.com/ 
Embase  
1. 'chlamydiasis'/exp NOT ('lymphogranuloma venereum'/exp OR 'trachoma'/exp) AND 
[humans]/lim AND [embase]/lim AND [1990-2012]/py 
2. 'prevalence'/exp NOT ('human immunodeficiency virus prevalence'/exp OR 
'seroprevalence'/exp OR 'parasite prevalence'/exp) AND [humans]/lim AND [embase]/lim 
AND [1990-2012]/py 
3. 'europe'/de OR 'eastern europe'/de OR 'western europe'/de OR 'austria'/exp OR 'baltic 
states'/exp OR 'belgium'/exp OR 'bulgaria'/exp OR 'cyprus'/exp OR 'czech republic'/exp 
OR 'czechoslovakia'/exp OR 'france'/exp OR 'germany'/exp OR 'greece'/exp OR 
'hungary'/exp OR 'ireland'/exp OR 'italy'/exp OR 'luxembourg'/exp OR 'malta'/exp OR 
'netherlands'/exp OR 'poland'/exp OR 'portugal'/exp OR 'romania'/exp OR 'slovakia'/exp 
OR 'slovenia'/exp OR 'yugoslavia'/exp OR 'scandinavia'/exp OR 'spain'/exp OR 'united 
kingdom'/exp OR 'switzerland'/exp OR 'iceland'/exp OR 'liechtenstein'/exp OR 
'australia'/de OR 'canada'/de OR 'new zealand'/de OR 'united states'/de OR 'japan'/de 
OR 'korea'/de OR 'israel'/de AND [humans]/lim AND [embase]/lim AND [1990-2013]/py 
4. #1 AND #2 AND #3 
Limits: 1990-current, humans, search in Embase only;; Homepage: http://www.embase.com 
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Popline 
CHLAMYDIA & PREVALENCE & (EUROPE / 'EUROPEAN UNION' / AUSTRIA / 
BELGIUM / BULGARIA / CYPRUS / 'CZECH REPUBLIC' / CZECHOSLOVAKIA / 
DENMARK / ESTONIA / FINLAND / FRANCE / GERMANY / 'GERMAN DEMOCRATIC 
REPUBLIC' / 'FEDERAL REPUBLIC OF GERMANY' / GREECE / HUNGARY / IRELAND / 
ITALY / LATVIA / LITHUANIA / LUXEMBOURG / MALTA / NETHERLANDS / POLAND / 
PORTUGAL / ROMANIA / SLOVAKIA / SLOVENIA / SPAIN / SWEDEN / 'UNITED 
KINGDOM' / YUGOSLAVIA / SWITZERLAND / NORWAY / ICELAND / LIECHTENSTEIN / 
AUSTRALIA / CANADA / 'NEW ZEALAND' / 'UNITED STATES OF AMERICA'/ JAPAN / 
KOREA / ISRAEL) NOT TRACHOMA 
Limits: search limited to title/keywords; Endnote Import Filter: 
http://db.jhuccp.org/popinform/basic.html; homepage: http://www.popline.org 
The Cochrane Library 
1. MeSH descriptor Chlamydia Infections explode all trees 
2. MeSH descriptor  Prevalence explode all trees 
3. MeSH descriptor  Europe explode all trees 
4. MeSH descriptor (AUSTRALIA OR CANADA OR NEW ZEALAND OR UNITED STATES 
OR JAPAN OR KOREA OR ISRAEL) 
6. #1 AND #2 AND #3 OR #4, limit to 1990 – 2012 
Homepage: http://onlinelibrary.wiley.com/o/cochrane/cochrane_search_fs.html 
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Appendix 2: Screening form for study eligibility
Endnote ID: ___ 
First author: ___ 
Checklist completed by: __ 
Inclusion for data extraction? 
- Yes;  
- Provisional;  
- No;  
- No, but interesting (retain for discussion or future use) 
Study design: 
- Cross-sectional study  
- Randomised controlled trial 
- Cohort study  
- Other: ___ 
Outcomes described for following population (Used for categories in Appendix 5) 
- General population 
- General population of a sub-national geographical area 
- Population other than in health care settings e.g. schools, institutions, prisons: ___ 
- Population in health care settings 
- Population in genitourinary medicine/sexually transmitted diseases clinic settings 
- Population of a specific subgroup e.g. commercial sex worker, men who have sex 
with men 
- People with comorbidity 
- Other, describe: ___ 
Reason for exclusion 
- Other than general population if general population are available for this country 
- Topic not relevant 
- Country not of interest 
- Narrative review 
- Specimen not from uro-genital tract 
- Age under 13 years 
- If USA/CAN/AUS/NZ (or other OECD high income countries) not general population 
- Study type not relevant 
- Other: ___ 
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Appendix 3: Flow chart of the selection process 
All publications identified 
N=  
MEDLINE n= , EMBASE n= ,  
Popline n= , Cochrane n=  
Additional searches n= 
Reference lists n=  
Experts n= 
Title and abstract screening 
N=  
ract screened
N= 886
Excluded: 
N= duplicates 
Excluded:    
N=  publications 
Topic not relevant, n=  
Country not of interest, n=  
Narrative Review, n=  
Specimen not from urogenital-tract, n=   
Age < 13 years, n=  
If AUS/CAN/NZ/USA or non-EU/EFTA-Europe, 
not general population, n=   
Other, n=  
Study type/design not relevant, n =  
Potentially eligible publications 
N=  
N= 
Excluded: 
N=  publications 
Narrative Review, n= 
If non-EU/EEA  
Not general population, n= 
Other, n= 
Study type/design not relevant, n= 
Laboratory or surveillance data, n= 
Self-reported data, n= 
Included in review 
Publications: N= 
EU/EEA n= (n= studies, n= countries) 
Non-EU/EEA n= (n= studies, n= countries) 
Excluded 
N=  publications 
Other settings in countries with general 
population study, n =  
Systematic reviews, references 
checked only, n= 
Full text screening 
N=  
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Appendix 4: Categories of study populations in studies with non-
population based sampling methods 
 Category 1A: defined random sample of the general population nationally, fulfilling all
relevant criteria to minimise risk of bias (Appendix 5)
 Category 1B: defined random sample of the general population nationally, NOT fulfilling
all relevant criteria to minimise risk of bias
 Category 2A: defined random sample of the general population of a sub-national
geographical region, fulfilling all relevant criteria to minimise risk of bias
 Category 2B: defined random sample of the general population of a a sub-national
geographical region, NOT fulfilling all relevant criteria to minimise risk of bias
 Category 3A: random or consecutive sample of a population similar to the general
population and not in health care settings, e.g. Schools, Universities, sport-clubs fulfilling
all relevant criteria to minimise risk of bias
 Category 3B: random or consecutive sample of a population similar to the general
population and not in health care settings, e.g. Schools, Universities, sport-clubs NOT
fulfilling all relevant criteria to minimise risk of bias
 Category 4A: random or consecutive sample of attenders at a non-GUM clinic healthcare
setting, fulfilling all the relevant criteria to minimise risk of bias
 Category 4B: random or consecutive sample of attenders at a non-GUM clinic healthcare
setting, NOT fulfilling all the relevant criteria to minimise risk of bias
 Category 5A: random or consecutive sample from a GUM clinic, fulfilling all the relevant
criteria to minimise risk of bias
 Category 5B: data from a GUM-clinic, NOT fulfilling all the relevant criteria to minimise
risk of bias
 Category 6A: sample of a specific subgroup at risk e.g. CSW, HIV-positive persons,
MSM, fulfilling all the relevant criteria to minimise risk of bias
 Category 6B: sample of a specific subgroup at risk e.g. CSW, HIV-positive persons,
MSM, NOT fulfilling all the relevant criteria to minimise risk of bias
 Category 7A: sample of patients with co-morbidity, such as other STD, symptoms of
urethritis or PID, infertility, EUG, abortion fulfilling all the relevant criteria to minimise risk
of bias
 Category 7B: sample of patients with co-morbidity, such as other STD, symptoms of
urethritis or PID, infertility, EUG, abortion NOT fulfilling all the relevant criteria to minimise
risk of bias
 Category 8A: other population, such as laboratory reports, specific subgroups which don’t
fit into the categories above, fulfilling all the relevant criteria to minimise risk of bias
 Category 8B: other population, such as laboratory reports, specific subgroups which don’t
fit into the categories above, NOT fulfilling all the relevant criteria to minimise risk of bias
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Appendix 5: Data extraction items 
Study design: 
- Cross-sectional study 
- Randomised controlled trial 
- Cohort study 
- Other, describe: ___ 
Inclusion criteria, describe: ___ 
Exclusion criteria, describe: ___ 
Select country from the list below: 
Austria; Belgium; Bulgaria; Cyprus; Czech Republic; Denmark; Estonia; Finland; France; 
Great Britain; Germany; Greece; Hungary; Ireland; Italy; Latvia; Lithuania; Luxembourg; 
Malta; Netherlands; Poland; Portugal; Romania; Slovakia; Slovenia; Spain; Sweden; Iceland; 
Liechtenstein; Norway; Switzerland; Australia; New Zealand; USA; Canada; other country, 
describe: ___ 
Methods 
Setting: General population of whole country or general population of a sub-national 
geographical area  
Describe methods and recruitment procedure: ___ 
Initial approach: 
- Mail 
- Telephone 
- Internet 
- Personal contact in household 
- Personal contact in health care settings 
- Other, describe:   
Date of study from ___ until___ 
Method of C. trachomatis detection: 
- Nucleic acid amplification test (NAAT) urine;  
- NAAT swab  
- Enzyme linked immunosorbent assay (ELISA) urine  
- ELISA swab   
- Immunofluorescence  
- Culture  
- Other, describe: ___ 
- Unclear  
Is ethical committee approval reported? Yes; No; Not applicable; Unclear 
Informed consent; Yes; No; Unclear 
Ethnic group: 
- White 
- Black including Caribbean, African 
- Indian, Pakistani and Bangladeshi 
- Chinese 
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- Other Asian 
- North African, Arab, Iranian 
- Romani 
- Not reported/unclear 
- Other including unknown, describe: ___ 
Sampling method: 
- Simple random sampling 
- Stratified random sampling 
- Multistage stratified random sampling 
- Consecutive sample 
- Convenience sample 
- Unclear 
- Other  
- Describe sampling method: ___ 
Outcomes reported in the study: 
- Prevalence 
- Response rate  
Outcomes reported for following subgroups (each outcome numbered): 
- Age groups combined 
- Age groups stratified 
- Men and women combined 
- Men and women separate 
- Men only 
- Women only 
- Ethnic groups separate 
- Certain ethnic group only 
- Number of lifetime partners any categorisation 
- Not specified 
- Others, not covered above: ___      
Description of target population: ___      
Description of source population: ___   
Reported for: Women and men combined; women only; men only 
Total number of eligible people__ 
Total number of people able to participate__     
Total number of people asked to participate /sent questionnaire to__ 
Total number of people agreed to participate/ filled in questionnaire__   
Total number of people asked for sample__     
Total number of people providing sample__ 
Total number of samples tested__ 
Total number of test results included in analysis__        
Do these numbers reported above add up logically? Yes; No; Unclear   
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How were missing data handled? Describe: ___ 
Age range of participants in overall sample lower limit __; upper limit__ 
Has any multivariable analysis been done to examine factors associated with Chlamydia? 
Yes, No; Unclear; If yes describe characteristics analysed: ___  
Numerical outcomes 
Endnote ID:___ 
Outcome number   
Describe group: ___  
Country number for this outcome    
Setting 
- General population 
- General population of a sub-national geographical area   
- Describe setting: ___ 
Sex: Women and men combined; Only women; Only men  
Age group: (lower limit to upper limit of age group, write ’99’ if unknown) 
Specimen handed in: 
- Urine 
- Swab 
- Unclear/not reported 
- Other, describe:___   
Collection method 
- Specimen collected by physician 
- Self-collected specimen 
Ethnic group 
- White   
- Black, including Caribbean, African 
- Indian, Pakistani and Bangladeshi  
- Chinese  
- Other Asian 
- North African, Arab, Iranian  
- Romani   
- Other, describe: ___ 
- Not reported/unclear    
Raw data, if reported (write 999999 if not reported) 
- Number tested positive 
- Weighted number tested 
- Un-weighted number tested   
Outcome (for each reported numbered outcome) 
- Prevalence and 95%CI (lower limit, upper limit) 
- Response rate and 95%CI (lower limit, upper limit) 
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Appendix 6: Risk of bias assessment 
We will use a list of published items by Boyle for assessing the methodological risk of bias in 
prevalence surveys [15]. We will use the published criteria to determine whether the risk of 
bias has been addressed adequately, inadequately, or if there was insufficient information to 
judge. For some items, we developed our own criteria, reviewers assess methods 
independently and agree on category by consensus or adjudication.    
Items assessed 
Item and explanation Assessment Criteria 
*Is the target population
clearly defined? 
Target population is the 
population to which the main 
results of the study will be 
extrapolated. 
Adequate Target population is defined by shared 
characteristics, such as age, sex, residency, 
sexual activity 
Inadequate Characteristics of target population not 
described  
Unclear Characteristics insufficiently defined 
Is the source population 
clearly defined?† 
Source population is the 
population from which 
investigators selected the 
random sample. 
Adequate Characteristics of the source population are 
clearly defined, e.g. by age, sex, residency, 
sexual activity 
Inadequate Characteristics of source population not 
described  
Unclear Characteristics insufficiently defined 
*Was probability sampling
used to select the sample? 
Adequate Simple, stratified or multistage random 
sampling methods described  
Inadequate Convenience sample or other non-random 
sampling method described  
Unclear Methods not described in sufficient detail to 
determine if probability sampling used 
Is the source population an 
adequate sample of the 
target population? † 
Yes If you can compare data about each and 
decide that there are no substantial 
differences, or the authors describe them as 
being similar  
No If you or the authors conclude that there are 
important differences between the source 
and the target population  
Unclear No description or unclear if there are 
important differences 
Are the socio-demographic Adequate Comparison done and socio-demographic 
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characteristics of responders 
and non-responders 
similar?* 
characteristics are described as ‘similar’ or 
no important differences observed  
Inadequate No comparison done, or comparison shows 
important differences between responders 
and non-responders 
Unclear Insufficient information to decide 
Sample size calculation 
described?† 
Yes A sample size calculation is described to 
show acceptable precision 
No No sample size calculation 
Unclear Insufficient information provided 
Adequate sample size 
achieved?† 
Yes Achieved sample size is similar to the 
sample size calculation 
Unclear, 
probably yes 
No sample size calculation described, but 
precision of primary outcome judged 
acceptable 
Unclear, 
probably no 
No sample size calculation described, but 
precision of primary outcome judged 
unacceptable 
Response rate* 
Number tested/ Number 
asked to participate or sent 
questionnaire to. If other 
numbers are used to 
calculate the response rate, 
do not calculate the 
response rate. 
≥80% Described by Boyle as acceptable [15] 
70-79% Categories defined by reviewers to describe 
response rates 
<70% 
Valid standardised 
questionnaire for data 
collection used?* 
Adequate Authors state that questionnaires for data 
like age, sex and risk behaviour are valid for 
all participants  
Inadequate Authors state that different questionnaires 
used for different study groups, e.g. by age, 
sex and risk behaviour, or non-validated  
Unclear Insufficient information provided 
NAAT used for C. 
trachomatis detection?† 
Yes Includes: PCR (including RT-PCR, 
transcription mediated amplification), 
branched DNA tests, ligase chain reaction, 
strand displacement analysis 
University of Bern, 28.12.2013 20 
No Other diagnostic test described 
Not described No information given about test used 
Special features of sampling 
design were accounted by 
the use of special statistical 
methods?* 
Special statistical methods 
include weighting procedures 
to adjust for sampling 
probabilities.  
Adequate Either, special features were accounted for 
by appropriate statistical methods, or special 
methods were not needed because simple 
random sampling used.  
Inadequate Complex sampling used but not accounted 
for by appropriate statistical methods 
Unclear 
Confidence intervals 
included?* 
Yes Reported by authors 
No Not reported by authors 
Data provided to calculate 
confidence interval?* 
Yes Simple random sampling and raw numbers 
(positive tests/total number of test results) 
provided 
No Simple random sampling but no raw 
numbers 
Not relevant Complex sampling method with confidence 
intervals calculated by authors 
* Items included in assessment tool and criteria for assessment adapted from descriptions by
Boyle [15]; 
† Items added for this systematic review and criteria developed by review team. 
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1 
Supporting Information Table S1
2 
Bibliography of primary and associated publications, by region and country in alphabetical order 
Study name, 
reference 
Main publication Additional publications 
Croatia 2011 
[19] 
Bozicevic I, Grgic I, Zidovec-Lepej S, 
Cakalo JI, Belak-Kovacevic S, Stulhofer A 
et al. (2011) Urine-based testing for 
Chlamydia trachomatis among young 
adults in a population-based survey in 
Croatia: feasibility and prevalence. BMC 
Public Health 11: 230. 10.1186/1471-
2458-11-230 [doi].. 
Denmark 1998 
[26] 
Ostergaard L, Andersen B, Olesen F, 
Moller JK (1998) Efficacy of home 
sampling for screening of Chlamydia 
trachomatis: randomised study. BMJ 
317(7150): 26-27. 
Ostergaard L, Andersen B, Moller JK, Olesen F (2000) Home sampling versus 
conventional swab sampling for screening of chlamydia trachomatis in women: 
A cluster-randomized 1-year follow-up study. Clin Infect Dis 31(4): 951-957. 
Denmark 1999 
[27] 
Munk C, Morre SA, Kjaer SK, Poll PA, 
Bock JE, Meijer, CJ et al. (1999) PCR-
detected Chlamydia trachomatis 
infections from the uterine cervix of 
young women from the general 
population: prevalence and risk 
determinants. Sex Transm Dis 26(6): 325-
328. 
Kjaer SK, van den Brule AJ, Bock JE, Poll PA, Engholm G, Sherman ME et al. 
(1996) Human papillomavirus--the most significant risk determinant of cervical 
intraepithelial neoplasia. Int J Cancer 65(5): 601-606. 
Denmark 2001     
[28] 
Bennedsen M, Nygard B, Berthelsen L, 
Jensen JS, Lind I (2001) [Prevalence of 
Chlamydia among young men. A 
screening among men liable for military 
service and coming before the military 
board]. Ugeskr Laeger 163(34): 4583-6. 
Denmark 2002  
[29] 
Andersen B, Olesen F, Moller JK, 
Ostergaard L (2002) Population-Based 
Strategies for Outreach Screening of 
Urogenital Chlamydia trachomatis 
Infections: A Randomized, Controlled 
Trial. J Infect Dis 185(2): 252-258. 
Moller JK, Andersen B, Olesen F, Lignell T, Ostergaard L (1999) Impact of 
menstrual cycle on the diagnostic performance of LCR, TMA, and PCE for 
detection of Chlamydia trachomatis in home obtained and mailed vaginal flush 
and urine samples. Sex Transm Infect 75(4):228-230. 
Andersen B, van Valkengoed I, Sokolowski I, Moller JK, Ostergaard L, Olesen F 
(2011) Impact of intensified testing for urogenital Chlamydia trachomatis 
infections: a randomised study with 9-year follow-up. Sex Transm Infect 87(2): 
156-161. 
Estonia 2008     
[30] 
Uuskula A, Kals M, Denks K, Nurm UK, 
Kasesalu L, Dehovitz J et al.(2008) The 
prevalence of chlamydial infection in 
Estonia: a population-based survey. 
International Journal of STD AIDS 19(7): 
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participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
3 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
3 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow‐up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
4 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
4 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
Online 
resource 1 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta‐analysis).  
4 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
5 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
5 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
5 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  5 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta‐analysis.  
5-6 
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Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
6 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre‐specified.  
6 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
6 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
Table 1 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Online 
resource 3 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Fig 2 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Fig 3-4 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Fig 5-6 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  8 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
8 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
9 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  9-11 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
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